Know Cancer

forgot password

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors

Phase 1
18 Years
Not Enrolling
Tumors, Lymphoma

Thank you

Trial Information

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors

Heat shock protein 90 (Hsp90) is an ubiquitous molecular chaperone protein that is involved
in folding, activation, and assembly of many proteins, including key mediators of signal
transduction, cell cycle control, and transcriptional regulation. In cancer cells that are
dependent upon Hsp90 client proteins, the degree to which clients are inhibited correlates
closely with induction of growth inhibition and apoptosis with Hsp90 inhibitory drugs. The
active pharmaceutical ingredient of CNF2024, CF1983 mesylate, is a synthetic, new chemical
entity designed to inhibit Hsp90. CF1983 hada strong affinity for tumor derived Hsp90 and
weaker affinity for Hsp90 isolated from normal cells or recombinant Hsp90.

Inclusion Criteria:

- Histologically or cytologically confirmed solid tumor which has failed standard
therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which
effective therapy is not available

- At least 18 years of age

- Hematology: Absolute neutrophil count (ANC) > 1500 cells/mm3, platelet count >
100,000 cells/mm3 and hemoglobin >= 9 gm/L

- Hepatic: Bilirubin < 1.5 X upper limit of normal (ULN); alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver
metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) < 5.0 X ULN.

- Renal: Serum creatinine levels < 2.0 mg/dL or creatinine clearance > 60 mL/min

- Coagulation: international normalized ratio (INR) < 1.5 times normal

- Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels

- Normal electrocardiogram (ECG) with QTc <= 450 msec for men and <= 470 msec for women

- Estimated life expectancy of at least 3 months as determined by the Investigator

- Eastern Cooperative Oncology Group (ECOG) performance status <= 2

- Male and female patients of childbearing potential must practice effective
double-barrier contraception during the study and continue contraception for 3 months
after their last dose of study drug. Male patients must agree to not have
intercourse with pregnant or nursing women during the study and for 3 months after
their last dose of study drug, unless using double-barrier contraception. The only
exceptions to double-barrier contraception are: Patient or partner is surgically
sterile,female patient is postmenopausal for at least 1 year before screening or
patient abstains from sexual intercourse, at the discretion of the Investigator

Exclusion Criteria:

- Pregnant or nursing women, women of child-bearing age not using reliable means of

- Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less
from chemotherapy-induced toxic effect, except alopecia, is required.

- Participation in any investigational drug study within 28 days prior to CNF2024

- Active infection requiring intravenous antibiotic treatment

- Patients with second malignancy requiring active treatment (except hormonal therapy)

- Concurrent severe or uncontrolled medical disease (i.e., systemic infection,
diabetes, hypertension, coronary artery disease, congestive heart failure)

- Active symptomatic fungal, bacterial and/or viral infection including active HIV or
viral (A, B or C) hepatitis

- Problems with swallowing or malabsorption

- Chronic diarrhea (excess of 2-3 stools/day above normal frequency)

- Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease,
or hemorrhagic coloproctitis

- Major surgery of the stomach or small intestine

- Adrenal dysfunction > Grade 2

- Patients with diabetes (your doctor will discuss if you are eligible for this study)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose (MTD)

Outcome Time Frame:

Dose escalation will proceed according to the predetermined scheme until the stopping dose (dose > MTD) is reached due to dose limiting toxicities (DLT) occurring during the first 4-week course of treatment.

Safety Issue:


Principal Investigator

Biogen Idec Medical Monitor, MD

Investigator Role:

Study Director

Investigator Affiliation:

Biogen Idec


United States: Food and Drug Administration

Study ID:




Start Date:

February 2006

Completion Date:

April 2009

Related Keywords:

  • Tumors
  • Lymphoma
  • Hsp90 inhibitor
  • CNF2024
  • Advanced Solid Tumors
  • Lymphoma



Research Site Mesa, Arizona  
Research Site Danbury, Connecticut  
Research Site Abilene, Texas